While the frequency of CD34+ and CD117+ cells remain unchanged between untreated and treated mice (Additional file 6: Figure S6), significant reduction of absolute AML count was observed in the peripheral blood, spleen but not BM upon Sorafenib and Regorafenib treatment (Fig. 5c). This evidence concerns the gene KIT and acute myeloid leukemia.